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LOW-DOSE RADIATION-INDUCED PROTECTIVE PROCESS AND
IMPLICATIONS FOR RISK ASSESSMENT, CANCER PREVENTION, AND
CANCER THERAPY
B. R. Scott  Lovelace Respiratory Research Institute
 A low-dose protective apoptosis-mediated (PAM) process is discussed that appears to
be turned on by low-dose gamma and X rays but not by low-dose alpha radiation. PAM is
a bystander effect that involves cross-talk between genomically compromised [e.g.,
mutants, neoplastically transformed, micronucleated] cells and nongenomically compro-
mised cells. A novel neoplastic cell transformation model, NEOTRANS3, is discussed that
includes PAM. With NEOTRANS3, PAM is activated by low doses and inhibited by moder-
ate or high doses and is, therefore, a hormetic process. A low-dose region of suppression
of the transformation frequency below the spontaneous frequency relates to the hormet-
ic zone over which PAM is presumed to operate. The magnitude of suppression relates to
what is called the hormetic intensity. Both the hormetic intensity and width of the hormet-
ic zone are expected to depend on dose rate, being more pronounced after low dose rates.
It is expected that PAM likely had a significant role in the following observations after
chronic irradiation: (1) what appears to be a tremendous reduction in the cancer inci-
dence below the spontaneous level for Taiwanese citizens residing for years in cobalt-60
contaminated apartments; and (2) the published reductions in the lung cancer incidence
below the spontaneous level in humans after protracted X irradiation and after chronic
gamma plus alpha irradiation. Implications of PAM for cancer prevention and low-dose
cancer therapy are briefly discussed.
Keywords: Low-dose radiation, hormesis, bystander effect, adaptive response
INTRODUCTION
The shape of the dose-response curve for stochastic effects (muta-
tions, neoplastic transformation, and cancer) of exposure to low doses of
ionizing radiation or genotoxic chemicals has been the topic of continu-
ous debate (Kondo 1999; Calabrese and Baldwin 2003a,b; Feinendegen et
al. 2004; Pollycove 2004; Sykes et al. 2004). The key discussion relates to
whether the linear nonthreshold (LNT) model for low-dose extrapola-
tion of cancer risk is valid (Ootsuyama and Tanooka 1993; Azzam et al.
1996; Tanooka 2000; NCRP 2001).
With the LNT hypothesis, any amount of carcinogen exposure increas-
es one’s risk of cancer. Now there is growing evidence from epidemiolog-
ical, experimental, and mathematical modeling studies that does not sup-
port the general use of the LNT model for central estimation of cancer
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risks at low doses of low linear-energy-transfer (LET) radiation (Scott et al.
2003; Scott 2004; Scott et al. 2004). Instead, the results support for adults
the existence of hormetic-type, dose-response relationships with low doses
and dose rates being protective and high doses causing harm.
Here, a novel approach is used to obtain dose-response functions for
cancer relative risk (RR) estimation that allow for hormetic-type dose
responses. The approach is based on the previous demonstration of sim-
ilar dose-response relationships for the RR for cancer induction in
humans and for induced neoplastic transformation in vitro (Redpath et al.
2001). The recently introduced, third-generation, neoplastic transforma-
tion (NEOTRANS3) model (Scott 2004) for low-dose, low-LET radiation-
induced stochastic effects (genomic instability, mutations, neoplastic
transformations) is used to develop RR relationships for neoplastic trans-
formation after single radiation (low- or high-LET) or mixed radiations
(low- and high-LET). The RR relationships for neoplastic transformation
are then adapted for application to cancer RR estimation in irradiated
humans. Implications of the research findings for cancer prevention and
low-dose cancer therapy are briefly discussed.
The NEOTRANS3 model is first introduced, including a description
of mathematical relationships associated with radiation-induced neoplas-
tic transformation after brief or protracted exposure to low-LET radia-
tion. RR relationships for neoplastic transformation are then developed
for combined exposure to high-LET alpha and low-LET gamma radia-
tion. The RR relationships for neoplastic transformation are then adapt-
ed for application to cancer RR in humans for combined, chronic expo-
sure to alpha and gamma radiation. The focus is on characterizing
hormetic-type, RR dose-response relationships for specific stochastic
effects (neoplastic transformation and cancer).
NEOTRANS3 MODEL
The NEOTRANS3 model (Scott 2004) is a refinement of the NEO-
TRANS2 model (Scott et al. 2004) which only addressed brief exposures
at high rates. In addition to allowing for chronic exposure at low rates,
NEOTRANS3 also allows for varying susceptibilities based on genetic
background.
Genomic Instability States
The NEOTRANS3 model (Figure 1), like its predecessor models
NEOTRANS1 (Scott 1997; Shöllnberger et al. 2001) and NEOTRANS2
(Scott et al. 2004), links neoplastic transformation potential to the
genomic instability status of cells. Such models were given the general
name “genomic instability state” models (Scott 1997; Shöllnberger et al.
2001). In addition to a stable genome for resistant cells, NEOTRANS3
involves three types of genomic instability considered to be important
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among hypersensitive cells that respond to low radiation doses: (1) nor-
mal-minor instability (NMI) associated with normal cell function and nor-
mal genome status, (2) transient-problematic instability (TPI) associated
with genomic damage that may sometimes be repaired without error but
can be misrepaired, and (3) persistent-problematic instability (PPI) that
arises from misrepair that yields viable mutants. Thus, PPI can be passed
to progeny, increasing their potential for neoplastic transformation.
Presently, the model structure does not include a spontaneous transition
from the NMI to the TPI state. This is because radiation-associated tran-
sitions are assumed to be far more likely over the exposure period con-
sidered. The model, however, does allow for spontaneous transition (mis-
repair related) from the TPI to the PPI state.
For the dose ranges of interest (low doses), it was assumed that hyper-
sensitive cells are much more likely to be impacted than are resistant cells
in the target cell population. Thus, newly induced mutants and transfor-
mants are much more likely to arise from hypersensitive cells than from
resistant cells. Radiation-induced transitions presently relate only to
hypersensitive cells.
A key feature of the NEOTRANS3 model is the inclusion of the previ-
ously introduced protective apoptosis-mediated (PAM) process (Scott
2004). PAM is a bystander effect involving cross-talk between genomical-
ly compromised (e.g., mutants, transformants, micronucleated cells, etc.)
and nongenomically compromised cells leading to intercellular induc-
FIGURE 1. NEOTRANS3 model transitions for hypersensitive cells that respond to low-dose radia-
tion. Genomic instability states NMI, TPI, and PPI are explained in the text. Figure modified from
Scott (2004) to clarify normal apoptosis pathway. 
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tion of apoptosis among genomically compromised cells. PAM appears to
require several hours to be fully activated after a brief low-LET dose and
seems to last for at least a day after activation (Scott 2004).
Bauer (2000) has summarized what is known about the intercellular
induction of apoptosis among fibroblasts based on numerous studies of
his research group (Jürgensmeier et al. 1994; Bauer 1995, 1996; Langer et
al. 1996; Hipp and Bauer 1997; Englemann and Bauer 2000). The pro-
tective process involves a sophisticated system of interdependencies and
interactions of reactive oxygen and nitrogen species. The release of trans-
forming growth factor beta by transformed cells is a key early event.
Nontransformed cells, when activated, release a novel peroxidase and
nitric oxide. Superoxide anions generated and released by transformed
cells participate in the intercellular signaling and also make transformed
cells the target for intercellular induction of apoptosis (i.e., transformed
cells are selectively removed via apoptosis). The interactions of these mol-
ecules result in two currently known major signaling pathways to apopto-
sis that are based on hypochlorous acid/hydroxyl radicals and on nitric
oxide/peroxynitrite. Hydrogen peroxide plays a key role by fostering the
hypochlorous acid/hydroxyl radical pathway and by inhibiting the nitric
oxide/peroxynitrite pathway.
Several pathways to apoptosis are likely associated with PAM, with the
selected path depending on the cell type to be eliminated via apoptosis
(mutants, neoplastically transformed cells, micronucleated cells, etc.), its
cellular environment, and the nature of the damage to DNA (Scott 2004). 
Radiation-associated transitions among hypersensitive cells in NEO-
TRANS3 are summarized in Figure 1 for low-LET irradiation. Thus,
Figure 1 relates to a hypersensitive sub-fraction, f1, of cells at risk. Low-
LET radiation-induced genomic damage to cells with normal minor insta-
bility leads to new cells with TPI. Misrepair and error-free repair, and
apoptosis pathways are available for cells with TPI. However, the apopto-
sis associated with the TPI (called “normal apoptosis”) differs from PAM
because PAM is a bystander effect (Scott 2004). Misrepair leads to mutant
cells with PPI that have a heightened potential to produce progeny that
undergo neoplastic transformation.
Doses above a small stochastic threshold, DPAM, activate PAM, which
then selectively removes precancerous cells (spontaneous and newly
emergent transformants) as well as some other genomically compro-
mised cells from the target population. Above a dose-rate-dependent, sto-
chastic, low-LET radiation dose, Doff, PAM is inactivated. Thus, PAM is a
hormetic process that takes place in the individual-specific, hormetic
zone DPAM to Doff. Both DPAM and Doff can vary over in vitro replicates and
over different individuals (i.e., in vivo). Thus, they are properly charac-
terized by distributions rather than point estimates. Bayesian analysis
methods facilitate obtaining distributions for DPAM and Doff since the focus
B. R. Scott
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of Bayesian analyses is characterization of distributions (called posterior
distributions). Conventional regression analysis does not allow addressing
stochastic thresholds, although it allows addressing deterministic thresh-
olds when errors in the deterministic quantity are normally distributed.
The parameter α1 in Figure 1 when multiplied by the radiation dose
rate c, accounts for low-dose-induced genomic damage among the hyper-
sensitive cells in the population. The ability of radiation to produce ini-
tial damage to DNA is assumed not to depend on genetic background.
Rather, genetic background is assumed to influence the DNA damage
mitigation process and such influences are accounted for through other
model parameters.
The parameter μ1 governs the rate of commitment of damaged hyper-
sensitive cells to the activated error-free repair pathway. This repair path-
way is associated with normal repair, which is presumed to be activated by
radiation. The corresponding parameter for the misrepair pathway
(which competes with the error-free pathway in normal repair) is η1.
Misrepair leads to a variety of viable mutations (cells with PPI). Activated
normal repair includes base excision repair, nucleotide excision repair,
recombinational repair (homologous recombination, nonhomologous
end joining), and mismatch repair.
The parameter φ1 governs the rate of commitment of newly damaged
cells (including lethal mutations) to the normal apoptotic pathway.
However, unlike PAM, normal apoptosis is not a bystander effect (Scott
2004). In addition, PAM operates at low doses of low-LET radiation, while
normal apoptosis may occur both at low and high doses as well as after
high-LET irradiation. PAM appears not to occur after low doses of high-
LET alpha irradiation (Scott et al. 2004).
Typical units for α1 are mGy
–1. Typical units for μ1, η1, and φ1 are
min–1. The parameter f1 is dimensionless. These parameters are stochas-
tic (i.e., have distributions) but currently are not time dependent.
With the NEOTRANS3 model PAM, normal apoptosis, and normal
repair (error-free component) work together in guarding against genom-
ic instability.
• Normal apoptosis removes damaged cells before mutations arise. 
• The error-free component of normal repair eliminates DNA damage
but not damaged cells.
• PAM removes mutants, neoplastic transformants, and likely removes
other aberrant cells (e.g., micronucleated cells).
Thus, the indicated team of biological protectors provides powerful pro-
tection against adverse stochastic effects of exposure to genotoxic agents.
Others (Wolff 1998; Pant et al. 2003) have implied that a novel, possi-
bly error-free DNA repair mechanism rather than PAM may be responsi-
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ble for low-dose-induced protection against mutations and neoplastic
transformation. This hypothetical, essentially error-free repair process,
has been called super repair (Scott 2004). The postulated existence of
super repair is mainly related to the fact that inhibition of DNA repair
inhibits the low-dose-associated protection against stochastic effects.
However, it was pointed out (Scott 2004) that inhibition of DNA repair
may also inhibit PAM. Further, it was demonstrated (Scott 2004) that the
experimental data for neoplastic transformation after inhibition of DNA
repair were adequately predicted by the NEOTRANS3 model when one
simply assumed that inhibition of DNA repair also inhibits PAM. It was
also pointed out that it is highly unlikely that the clustered DNA damage
(e.g., multiple closely spaced double-strand breaks) induced by ionizing
radiation can be repaired without any errors and that no new, complete-
ly error-free repair processes have been observed. Further, homologous
recombination does not operate throughout the cell cycle. In addition,
there is an apparent absence of DNA repair after very low doses of low-
LET radiation (Rothkamm and Löbrich 2003). 
Brief or Protracted Exposure to Low-LET Radiation
For brief exposure to small or moderate doses, D, of low-LET radia-
tion, the expected transformation frequency per surviving cell (TFSC) is
given in the context of NEOTRANS3 by (Scott 2004):
TFSC(D) = T0, for D < DPAM,
TFSC(D) = (1 – f0){T0 + [(1 – T0)]kTD }, for DPAM ≤D < Doff ,
TFSC(D) = T0 + [(1 – T0)]kTD, for D ≥ Doff , (1)
where the slope parameter kT is given by:
kT = f1α1η1Ω/(μ1 + η1 + φ1). (2)
The subscript T indicates the endpoint neoplastic transformation, and
the parameter f1 is the fraction of hypersensitive cells. Equation 1 applies
to both brief and protracted exposures to low-LET radiation. A similar
relationship would apply to mutations.
The parameters Ω, μ1, η1, and φ1 as well as the efficiency of the PAM
process are assumed to be influenced by genetic background. In addi-
tion, for in vivo exposure, Ω may differ for different tissues. Thus, kT
depends on genetic background and target tissue in vivo.
The parameter f0 is the fraction of the spontaneous genomically com-
promised cells (e.g., spontaneous transformants) removed via radiation-
induced PAM and has been given the special name “protection factor”
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(PROFAC) (Scott et al. 2003). The PROFAC is a measure of the hormetic
intensity of the PAM process. For f0 = 0 (i.e., no PAM), Equation 1 reduces
to the LNT model. The PROFAC is expected to increase with decreasing
dose rate (e.g., keeping dose constant and increasing the exposure time).
A PROFAC also can be used to characterize mutation frequency and can-
cer incidence (or mortality) dose-response relationships when adaptive
responses occur and are associated with hormetic processes.
The currently used data permit estimating kT only, not the individual
parameters on the right-hand side of Equation 2. However, previously it
has been shown that with a rich data set (i.e., one with numerous doses
over the range of interest and several dose rates), one can indeed esti-
mate basic model parameters (Scott 1997; Schöllnberger et al. 2001).
As already indicated, for in vivo studies of neoplastic transformation
or mutations, DPAM is stochastic. Such stochastic thresholds impact the
shape of the dose-response curve for the stochastic effect considered. For
in vitro studies, currently available low-dose data place the upper bound
for DPAM below 1 mGy (0.001Gy) (Scott 2004).
For doses below DPAM, misrepair is currently assumed not to occur
(Scott et al. 2004; Scott 2004). For this dose range, damaged cells with TPI
are presumed to undergo normal apoptosis. For a dose just above DPAM
and for a specific irradiated individual and target tissue in that individual,
the dose-response curve drops down from T0 to (1 – f0)T0 and remains
roughly flat for a range of doses; however, for low-dose-rate irradiation,
the range over which the dose-response curve remains roughly flat is
expected to be extended, possibly to several Gy. Because DPAM varies in
vivo over different individuals (and for in vitro replicates), the dose-
response curve for neoplastic transformation derived from averaging
over different individuals (or over in vitro replications) will not display the
sudden drop indicated but will initially decrease rather smoothly. A simi-
lar smooth rise in the dose-response curve also will be associated with the
stochastic dose Doff . In addition, f0 is expected to increase as the time peri-
od over which a given dose is delivered increases (i.e., with decreasing
dose rate). Thus, f0 should be considered to depend on low-LET radiation
dose rate and on duration of exposure.
Combined Exposure to Low Doses of Alpha and Gamma Radiations
Here RR relationships are first developed for neoplastic transforma-
tion induced by combined high-LET alpha and low-LET gamma irradia-
tion. From the relationships for combined exposure, RR relationships for
individual radiations can also be expressed. Results obtained for neoplas-
tic transformation facilitate modeling RR for cancer induction in
humans.
Currently available data indicate that PAM is not activated (i.e., f0 = 0)
by low doses of high-LET alpha radiation (Scott 2004; Scott et al. 2004).
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However, for combined exposure to alpha and gamma radiation, it is
assumed that PAM could be activated by the gamma-ray component of
the dose.
In this section and throughout the remainder of the paper, the sub-
script H is used for high-LET alpha radiation and the subscript L for low-
LET gamma radiation. Thus, for alpha radiation kT is replaced with kT,H
and for gamma rays kT is replaced with kT,L. For the combined alpha and
gamma irradiation considered here, it is assumed that the gamma-ray
dose is in the hormetic zone (DPAM < DL < Doff ) so that PAM is activated.
Thus, the transformation frequency per surviving cell for the combined
exposure is given by:
TFSC(DL, DH) = (1 – f0){T0 + (1 – T0)(kT,LDL + kT,HDH)}. (3)
The term enclosed within the aggregation signs, {}, is just the joint prob-
ability of a spontaneous, gamma-ray-induced, or alpha-radiation-induced
transformant among surviving cells. The term (1 – f0) is just the proba-
bility that a transformant arising for any reason will survive activated
PAM.
The RR relationship that corresponds to Equation 3 is given by:
RRT(DL, DH) = (1 – PROFACL){T0 + (1 – T0)(kT,LDL + kT,HDH)}/T0 . (4)
where the hormetic intensity PROFACL has replaced f0 . For only low-dose
gamma irradiation the RR is given by RRT(DL,0). Similarly, for only alpha
radiation, the RR is given by RR(0,DH) but with the PROFACL set to zero,
which yields the LNT model.
Figure 2 shows results of application (Scott 2004) of Equation 4 to
data of Redpath et al. (2001) for gamma-ray-induced neoplastic transfor-
mation of HeLa × skin fibroblast human hybrid cells. Bayesian inference
methods were used to fit the NEOTRANS3 model to the data (Scott 2004;
Scott et al. 2004). With the Bayesian approach, model parameters are
assigned prior distributions which are operated on via a likelihood func-
tion that depends on the dose-response model being used and on the
observed biological effects data. The outputs are posterior distributions
of model parameters (including Doff) that have associated statistics includ-
ing posterior mean, standard deviation, and specific percentiles. Markov
chain Monte Carlo (MCMC) methods have been used to implement the
Bayesian analyses (Scott 2004; Scott et al. 2004).
The data in Figures 2 did not permit estimating the distribution for
DPAM because of the absence of sufficient data at very low doses (< 1 mGy).
All nonzero doses used experimentally were assumed to exceed the max-
imum for DPAM . The 5% and 95% values for the posterior distribution for
Doff were 155 mGy and 245 mGy, respectively. The associated posterior
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mean of 200 mGy is essentially the starting value assigned in the MCMC
analysis, indicating that a larger data set is needed in order to reliably esti-
mate the mean for the stochastic variable Doff .
For the hormetic zone it is expected that KT,HDH >> kT,LDL so that a
reasonable approximation for Equation 4 is:
RRT(DL, DH) ≈ (1 – PROFACL){1 + [(1 – T0)/T0] kT,H DH }, (5)
which depends on the high-LET alpha radiation dose but not on the low-
LET gamma ray dose. It is expected that for protracted exposure at low
rates, the hormetic zone can be greatly extended possibly with Doff
exceeding 1000 mGy (Scott 2004). Thus, Equation 5 is expected to apply
to chronic exposure to low, moderate, and possibly higher doses.
It follows from the above that:
RRT(DL, 0) ≈ 1 – PROFACL, (6)
and
RRT(0,DH) = 1 + [(1 – T0)/T0]kT,H DH . (7)
Figure 3 shows results of application of Equation 6 to the low-dose
data (0 to 100 mGy) in Figure 2. The horizontal solid line through the
data is just the mean of the nonzero dose data (5 points) for RRT. The
dashed lines are the associated 95% confidence region for the indicated
mean.
In the next section, Equation 5 is used to obtain a similar relationship
for RR for cancer induction in humans by combined exposure to alpha
and gamma radiation. Justification for this approach to obtaining RR rela-
tionships for cancer induction is also provided in the next section.
FIGURE 2. Relative risk (RR) for gamma-ray-induced neoplastic transformation of HeLa x skin
fibroblast human hybrid cells based on data of Redpath et al. (2001). The indicated error bars were
obtained by dividing the 95% confidence values for the transformation frequency by the mean spon-
taneous frequency. Thus, uncertainty in the spontaneous frequency is not reflected in the error bars.
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RELATIVE RISK FOR CANCER INDUCTION IN HUMANS
Redpath and colleagues (2001) have shown that the dose-response
relationship for the RR for low-dose, radiation-induced neoplastic trans-
formation in vitro has a similar shape as for the RR for cancer induction
in humans. This implies that dose-response functions for RR for neoplas-
tic transformation could be adapted for application to RR for cancer
induction in humans, thereby facilitating low-dose risk extrapolation
(e.g., into the hormetic zone). This is assumed to be true for gamma radi-
ation, alpha radiation, and for combinations of both. Mathematical rela-
tionships obtained for gamma radiation are assumed to also apply to
X rays, beta particles, and possibly other forms of low-LET radiation.
Whether or not results obtained for alpha radiation apply to neutrons is
unclear because neutrons tend to produce secondary gamma rays.
For low-dose induction of cancer in humans by combined chronic
gamma plus alpha irradiation, it is assumed that an equation similar in
structure to Equation 5 applies based on the above indicated observa-
tions by Redpath et al. (2001). Thus, kT is replaced with a corresponding
slope parameter KC for cancer induction. Throughout this section the
subscript C is used to indicate cancer induction. The spontaneous trans-
formation frequency, T0, is replaced with the baseline cancer incidence,
B, for the population considered. Use of PROFACL is maintained but with
the understanding that here it applies to protection against cancer occur-
rence and may differ in value from the protection factor associated with
protection against neoplastic transformation. For protection against can-
cer occurrence, immune system stimulation by low-dose radiation may
provide added protection (Pollycove 2004; Liu 2004) in addition to PAM.
If follows that for cancer induction by chronic low-dose alpha plus
gamma irradiation where gamma-ray doses are in the hormetic zone that:
RRC(DL, DH) ≈ (1-PROFACL) {1 + [(1 – B)/B]KC,H DH }. (8)
FIGURE 3. Results of application of the approximation in Equation 6 to the low dose RR data (with-
in hormetic zone) of Redpath et al. (2001) in Figure 2.
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For cancer induction by chronic gamma irradiation within the hormetic
zone, the relative risk, RR is just:
RRC (DL, 0) ≈ 1 - PROFACL. (9)
For chronic exposure to alpha radiation only and assuming PAM is not
activated by alpha radiation one gets:
RRC(0, DH) = 1 + [(1 – B)/B]KC,H DH. (10)
Equation 10 is consistent with the LNT hypothesis and there is no
hormetic zone. Figure 4 shows results of the application of Equation 9 to
data for the RR for lung cancer mortality among 64,172 Canadian tuber-
culosis patients (fluoroscopy cohort study) who received fractionated
(protracted) exposure to diagnostic X rays. The data were reported by
Howe (1995). Only a modest hormetic intensity (PROFACL = 0.16 ± 0.03)
was implicated against lung cancer. The smooth curve through the data
points for DL > 0 is based on the mean of individual estimates of the dif-
ference 1 – PROFACL obtained from the four data points occurring
between 400 and 800 mGy. The dashed curves surrounding the central
curve are 95% confidence values for 1 – PROFACL.
Equation 8 was applied to RR data (Khokhryakov et al. 1996) for lung
cancer in humans (Mayak workers) after chronic exposure over years to
alpha plus gamma radiations. The data and modeling results are pre-
sented in Table 1. Model fitting was carried out via Bayesian inference
conducted with WinBUGS software (Schöllnberger et al. 2001; Scott
2004). The indicated analyses also involved use of MCMC. The prior dis-
tribution for PROFACL was uniform over the interval (0.7, 1). The prior
distribution for KC,H was uniform over the interval (1.0×10
–5/mGy,
4.0×10–4/mGy). Baseline incidence rates, B, were fixed at the means
FIGURE 4. Lung cancer mortality relative risk (RR) based on Canadian tuberculosis patients chron-
ically exposed to X rays. Data are from fluoroscopy cohort study of Howe (1995). Equation 9 was used
to fit the data.
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reported by Khokhryakov et al. (1996). Because dose groups were used
with rather wide dose ranges in some cases, doses were modeled as being
uniformly distributed over the dose intervals indicated in Table 1. Thus,
analyses were based on only two free parameters KC,H and PROFACL.
Cancer cases associated with a specific dose were assumed to have a
Poisson distribution.
After carrying out the initial 5000 MCMC iterations, a check was
made for the status of autocorrelations to assist in estimating how long a
chain needed to be run for convergence. Results indicated that on the
order of 500,000 iterations were needed. Instead, 1,000,000 iterations
were used with the first 800,000 treated as burn-in (i.e., discarded). 
The posterior mean for the slope parameter KC,H was 1.21×10
–4/mGy
(0.121/Gy). The associated standard deviation was 4.0×10–6/mGy. The
posterior mean for PROFACL was 0.86 ± 0.07, indicating that about 86%
of spontaneous lung cancers (including those associated with smoking)
were possibly prevented. Similarly, it appears that about 86% of lung can-
cer cases that would have occurred with exposure only to alpha radiation
were halted (did not occur) because of the chronic gamma irradiation.
Thus, the results are consistent with the view that chronic, low-dose-rate
gamma irradiation can turn on and prolong the PAM process.
How does the risk coefficient of 0.1 excess lung cancer cases per Gy
of alpha radiation compare to results from animal studies? Lundgren et
al. (1991) reported a value of 0.11 excess lung cancer cases per Gy for a
group of 70 F344/Crl rats that inhaled 239Pu, when the average dose to
the lung (lowest-dose group) was 0.13 Gy. For the next to lowest-dose
group (average dose of 0.26 Gy) the corresponding value was 0.16/Gy. In
the next to the highest-dose group (average dose 0.76 Gy) the corre-
sponding value was 0.053/Gy. For the highest-dose group (average dose
2.8 Gy), the corresponding value was 0.062/Gy. The average of these four
values is:
TABLE 1. Relative risk (RR) data for lung cancer incidence in Mayak Plutonium Facility workers.
Alpha radiation Bayesian Bayesian Bayesian 
dose interval Observed RRC posterior posterior 5% posterior 95% 
(mGy)a (mean baseline)b mean RRC ± SD value for RRC value for RRC
0-12 0.39 (41 ± 25)b 0.359 ± 0.073 0.246 0.487
12.1 - 50 0.53 (57± 41 ) 0.558 ± 0.092 0.418 0.721
51 - 200 1.58 (76 ± 55) 1.59 ± 0.14 1.36 1.84
201 - 800 4.65 (86 ± 93 ) 4.66 ± 0.23 4.29 5.05
801 - 3200 28.1 (99 ± 106) 28.1 ± 0.53 27.2 28.9
aDoses are absorbed doses averaged over the lung.
bNumbers within parentheses are baseline lung cancer cases per 100,000 persons per year; data
are from Khokhryakov et al. (1996).
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average = (0.11 + 0.16 .053 + 0.062) Gy–1/4 = 0.09625/Gy,
which is approximately 0.1/Gy, essentially the same as derived for the
Mayak workers! 
DISCUSSION
The NEOTRANS3 model includes the stochastic threshold, DPAM , and
the stochastic dose, Doff , which defined the stochastic width of the individ-
ual-specific (or replicate-specific) hormetic zone. Table 2 presents some
simulated data for a hypothetical in vitro neoplastic transformation study
whereby 10 replicates are used. The hypothetical data presented illustrate
the stochastic nature of the width of the replicate-specific hormetic zone.
DPAM was assumed to have a uniform distribution over the interval 0.1 to
1.0 mGy. Doff was assumed to have a uniform distribution over the interval
150 to 250 mGy. For the 10 replicates considered, the replicate-specific
width of the hormetic zone ranged from 164 to 226 mGy.
The NEOTRANS3 model was extended to address combined expo-
sure to alpha and gamma radiations. RR relationships developed for neo-
plastic transformation were adapted for application to cancer induction
in humans. Resulting equations were applied to lung cancer induction
among Mayak workers exposed over years to alpha and gamma radia-
tions. However, results obtained differed from those obtained by
Kreisheimer et al. (2003).
Kreisheimer et al. (2000, 2003) in using internal controls did not find
evidence for the existence of a low-dose hormetic zone in their studies of
lung cancer but rather concluded that the LNT model adequately
described the risk associated with alpha radiation. However, this conclusion
is likely due to their choice of using internal controls. For example, had the
lowest nonzero dose group in Table 1 been used as controls in the analysis
TABLE 2. Simulated data for width of hormetic zone associated with gamma-ray-induced neoplastic
transformation in hypothetical in vitro system.
Replicate DPAM (mGy) Doff (mGy) Width of hormetic zone (mGy)
1 0.42 216 216
2 0.56 226 225
3 0.74 199 198
4 0.75 186 185
5 0.85 227 226
6 0.25 164 164
7 0.84 211 210
8 0.22 202 202
9 0.70 194 193
10 0.98 219 218
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conducted in this paper, the conclusion would have been similar as was
arrived at by Kreisheimer et al. (2000, 2003). This is because the RR for the
lowest-dose group would have been rescaled from a value close to 1 – PRO-
FACL to a value of 1, leading to a much steeper dose-response curve for RR
when evaluated based on the LNT model fitted to the full range of doses
available. To see the protective impact of PAM, one needs a reference pop-
ulation not having significant low-LET radiation doses. Essentially all of the
Mayak workers were exposed to ionizing radiation related to activities that
took place at the facility as well as to environmental radionuclide contami-
nation associated with releases from the Mayak facility. 
Evidence for a low-dose hormetic zone has been reported for lung
cancer induction in association with chronic exposure to ionizing photon
radiation. Rossi and Zaider (1997) critically reviewed the literature on
radiogenic lung cancer and concluded that, “at radiation doses generally
of concern in radiation protection (< 2 Gy), protracted exposure to low-
LET radiation (X- or gamma-rays) does not appear to cause lung cancer.
There is in fact, indication of a reduction of the natural incidence.”
In a recent publication by Chen et al. (2004) the following is stated
related to the approximately 10,000 people who for years occupied
cobalt-60 contaminated apartments in Taiwan: 
“They did not suffer a higher incidence of cancer mortality, as the
LNT theory would predict. On the contrary, the incidence of cancer
deaths in this population was greatly reduced—to about 3% of the inci-
dence of spontaneous cancer death in the general Taiwan public. In addi-
tion, the incidence of congenital malformations was also reduced—to
about 7 percent of the incidence in the general public. These observa-
tions appear to be compatible with the radiation hormesis model.”
The indicated results suggest that very high hormetic intensity
(PROFACL > 0.95) can be associated with chronic exposure of humans at
low rates to gamma rays. However, these results should be considered pre-
liminary. Even so, the results are consistent with the view that PROFACL
increases as dose rate decreases and as the exposure time is increased.
Further, they suggest that PAM may also provide protection against con-
genital malformation. However, new research is needed to address this
possibility.
The Hanford Thyroid Disease Study did not find evidence of any
excess risk for thyroid cancer induction for persons living in the vicinity
of the Hanford facility who were exposed to beta radiation from radioac-
tive iodine released from the facility (USDHHS 2002). For doses in the
range of 0–100 mGy, risk was not correlated with dose and was less than
for the control group based on persons outside what was considered the
irradiation zone. In addition, for several health effects, the mean slope of
the risk versus dose relationship was negative (indicating a possible low-
dose hormetic zone).
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Animal data are also consistent with the possible existence of low-dose
hormetic zones for cancer induction by low-dose-rate, low-LET radiation
(Yamamato et al. 1998; Kondo 1999; Tanooka 2000; Yamamato and
Seyama 2000). In addition, Mitchel et al. (2003) have demonstrated that
low-dose gamma radiation increases the latency for spontaneous lym-
phoma formation in cancer-prone Trp53 heterozygous mice, which is
consistent with the existence of a low-dose hormetic zone. 
Knowledge of the existence of a low-dose hormetic zone associated
with low-LET radiation has important implications for cancer prevention
and for low-dose cancer therapy (Liu 2004). For populations at high risk
for cancer occurrence (e.g., heavy cigarette smokers, persons exposed to
high doses of chemical carcinogens, communities ingesting high levels of
carcinogens [e.g., aflatoxin] in their diet), the results presented suggest
that a little dab of gamma (or X) rays now and then could repeatedly acti-
vate PAM and thereby selectively remove precancerous cells from the
body. By removing precancerous cells, one would expect the cancer risk
to also decrease, possibly leading to extension of the latent period for
cancer occurrence in some cases, and possibly preventing cancer occur-
rences in other cases. The notion that low doses of low-LET radiation
(e.g. gamma or X rays) could act as a cancer preventive agent is novel.
Each dose of radiation would need to be in the hormetic zone and tim-
ing of the doses could be important.
Regarding low-dose therapy for cancer, it is recognized that cancer
cells seem to have at least partly lost the ability to undergo apoptosis. This
implicates their having a reduced ability to undergo PAM. Knowledge of
the molecular changes that prevent cancer cells from undergoing PAM
could lead to new molecular tools for reversing the inhibition of PAM,
thereby allowing for PAM to operate against existing cancer cells. This
could lead to novel low-dose therapy protocols for possibly eliminating
cancer without causing severe damage to normal tissue. The currently
used high-dose radiation therapy causes severe damage to normal tissue,
thereby limiting the success of the therapy.
Arsenic trioxide has been found to sensitize cancer cells to undergo-
ing apoptosis (Miller et al. 2002; Kang et al. 2004). This suggests that novel
cancer therapy strategies might involve combined exposure to low dose
arsenic trioxide (or other apoptosis sensitizing agents) and low-dose, low-
LET radiation. Sensitizing cancer cells to undergo apoptosis and then
using low-LET radiation to amplify the PAM process could possibly lead
to highly efficient killing of cancer cells while sparing normal tissue from
significant injury.
It is important to consider who might not benefit from PAM induc-
tion. Should there be members of an at-risk population for radiation
exposure, which do not already have significant numbers of genomically
compromised cells in their body, then for such persons, PAM activation
Low-dose-induced protective process
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may not occur and should it occur may not provide any real benefit. For
such individuals there may not exist a hormetic zone for low-dose-
induced stochastic effects. Possible candidates would be the embryo/
fetus, newborn, young children, and teenagers; as their bodies may not
contain significant numbers of genomically compromised cells for PAM
to be beneficial.
The existence of a low-dose hormetic zone for low-LET radiation-
induced stochastic effects means that low-dose risk extrapolation based
on the LNT model can lead to phantom excess risk at low doses; there-
fore, its use could lead to more harm than benefit to society. Such phan-
tom excess risks could also arise for combined exposure to low- and high-
LET radiation in circumstances where PAM is activated by the low-LET
component of the dose.
Results presented mainly focused on exposure to alpha or gamma
radiation or their combinations. Similar approaches as presented could
be used for exposure to a genotoxic chemical, combination of genotoxic
chemicals, and to radiation plus genotoxic chemicals. RR relationships
could be developed for neoplastic transformation and adapted to appli-
cation to RR for cancer induction in humans.
CONCLUSIONS
1. Evidence based on the NEOTRANS3 model was provided for the ex-
istence of a low-dose hormetic zone for neoplastic transformation
after exposure to low-LET radiation. The zone is explained on the
basis of activated PAM. 
2. The existence of a low-dose hormetic zone for low-LET radiation-
induced stochastic effects means that low-dose risk extrapolation
based on the LNT model can lead to phantom excess risk at low doses.
3. While no hormetic zone appears to be associated with low-dose alpha
irradiation, combined exposure to low doses of gamma rays and
alpha radiation can also be associated with a hormetic zone. 
4. The activation of PAM by low doses of radiation makes possible the
development of improved protocols for low-dose therapy for cancer
as well as for novel cancer prevention strategies for populations
already at high risk for cancer development.
5. Not everyone in an at-risk population to radiation exposure may ben-
efit from PAM activation. Persons that may fall into this category in-
clude the embryo/fetus, the newborn, young children, and teenagers
since they may not possess significant numbers of genomically com-
promised cells to benefit from PAM. 
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